# Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 4

#### MOMENTA PHARMACEUTICALS INC

Form 4

February 22, 2016

FORM (	4
--------	---

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB** 3235-0287 Number:

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

January 31, Expires: 2005

0.5

**OMB APPROVAL** 

Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

burden hours per response...

Estimated average

See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* WHEELER CRAIG A

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol

**MOMENTA** 

PHARMACEUTICALS INC

3. Date of Earliest Transaction

[MNTA]

\_X\_ Director 10% Owner

(Check all applicable)

02/19/2016

X\_ Officer (give title Other (specify

(Month/Day/Year)

below) President

C/O MOMENTA

(Last)

PHARMACEUTICALS, INC., 675 WEST KENDALL STREET

(Street)

02/19/2016

Stock

(First)

(Middle)

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year)

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

CAMBRIDGE, MA 02142

(City)	(State)	(Zip) Tabl	e I - Non-I	<b>Derivative</b>	Secur	ities Ac	quired, Disposed	of, or Benefic	ially Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securi on(A) or Di (D) (Instr. 3,	4 and (A) or	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/19/2016		S(1)	1,969	D	\$ 9.35 (2)	253,905	D	
Common	02/10/2016		G(3)	7.075	Ъ	\$	246.020	D	

 $S^{(3)}$ 7,875 D 9.37 D 246,030 (4)

Common 183,596 I Craig Stock

Wheeler Revocable

### Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 4

Trust

Craig A. Wheeler

Irrevocable

Trust

2014

Common Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

150,000

I

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Conversion or Exercise Security (Instr. 3) Price of Derivative

Security

3. Transaction Date 3A. Deemed (Month/Day/Year)

Execution Date, if

(Month/Day/Year)

5. TransactionNumber Code of (Instr. 8) Derivative

Securities Acquired (A) or

Disposed

(Instr. 3, 4, and 5)

of (D)

**Expiration Date** (Month/Day/Year)

6. Date Exercisable and 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5)

Deriv Secu Bene Own Follo Repo Trans (Insti

9. Nu

Amount

or Expiration Title Number of

Shares

**Reporting Owners** 

Reporting Owner Name / Address

Relationships

10% Owner Officer Director

Code V (A) (D)

Other

Date

WHEELER CRAIG A C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE, MA 02142

X

President

Date Exercisable

**Signatures** 

/s/ Marie T. Washburn as attorney in fact

02/22/2016

\*\*Signature of Reporting Person

Date

Reporting Owners 2

# Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 4

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This sale was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on August 12, 2014.
- This transaction was executed in multiple trades at prices ranging from \$9.13 to \$9.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the
- (2) average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- (3) This sale was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on September 10, 2015
  - This transaction was executed in multiple trades at prices ranging from \$9.08 to \$9.65. The price reported above reflects the weighted
- (4) average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.